Clinical TrialsAmadeo2025-01-31T10:29:05+00:00 Clinical Trials Efficacy of administering Streptococcus salivarius K12 as a powder formula in preventing respiratory infections in infants. Kryuchko and Tkachenko.2021 An open-label study to evaluate the effects of Streptococcus salivarius K12 given as a powder formula to prevent respiratory infections in young children. Kryuchko and Tkachenko.2021 The efficiency of respiratory probiotic Streptococcus salivarius K12 use in children with recurrent tonsillitis. Ilchenko et al.2020 Application of Streptococcus salivarius K12 probiotic strain in the treatment of acute tonsillopharyngitis in children. Kramarev et al.2020 Impact of Streptococcus salivarius K12 on nasopharyngeal and saliva microbiome: a randomized controlled trial. Sarlin et al.2020 Optional location therapy of chronic tonsillopharyngitis to achieve long-term remission. Bezshapochny et al.2020 Prevention of recurrent respiratory diseases in children with microaspiration syndrome. Ilchenko et al.2019 Experience with the clinical use of the respiratory probiotic Bactoblis® in children with secretory otitis media. Havrylenko et al.2019 Pilot study to explore the prophylactic efficacy of oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngo-tonsillar episodes in pediatric patients. Marini et al.2019 Clinical experience of Streptococcus salivarius K12 use for the prevention of pharyngotonsillitis and respiratory infections in children. Kryuchko and Tkachenko.2018 « Previous Page1 Page2 Page3 Page4 Next » Year All 2004 2005 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 All 2004 2005 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 Health Area Respiratory health Respiratory health
Efficacy of administering Streptococcus salivarius K12 as a powder formula in preventing respiratory infections in infants. Kryuchko and Tkachenko.2021
An open-label study to evaluate the effects of Streptococcus salivarius K12 given as a powder formula to prevent respiratory infections in young children. Kryuchko and Tkachenko.2021
The efficiency of respiratory probiotic Streptococcus salivarius K12 use in children with recurrent tonsillitis. Ilchenko et al.2020
Application of Streptococcus salivarius K12 probiotic strain in the treatment of acute tonsillopharyngitis in children. Kramarev et al.2020
Impact of Streptococcus salivarius K12 on nasopharyngeal and saliva microbiome: a randomized controlled trial. Sarlin et al.2020
Optional location therapy of chronic tonsillopharyngitis to achieve long-term remission. Bezshapochny et al.2020
Prevention of recurrent respiratory diseases in children with microaspiration syndrome. Ilchenko et al.2019
Experience with the clinical use of the respiratory probiotic Bactoblis® in children with secretory otitis media. Havrylenko et al.2019
Pilot study to explore the prophylactic efficacy of oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngo-tonsillar episodes in pediatric patients. Marini et al.2019
Clinical experience of Streptococcus salivarius K12 use for the prevention of pharyngotonsillitis and respiratory infections in children. Kryuchko and Tkachenko.2018
